Vera Therapeutics Q1 net loss widens to $121.03 million

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00
  • Vera Therapeutics posted a net loss of $121.03 million, widening from $51.69 million a year earlier; loss per diluted share deepened to $1.69 from $0.81.
  • Operating loss widened to $125.13 million as operating expenses climbed to $125.13 million, led by R&D spending of $86.01 million.
  • Net cash used in operating activities rose to $106.5 million from $54.4 million in the prior-year quarter; cash, cash equivalents, and marketable securities fell to $596.76 million at March 31.
  • FDA granted priority review for atacicept accelerated approval in adult IgA nephropathy, setting a PDUFA date of July 7, 2026; U.S. launch remains planned for mid-2026 pending approval.
  • Initial Phase 2 PIONEER basket-trial results are expected in Q2 2026, with pivotal two-year eGFR data from ORIGIN 3 due in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070730PRIMZONEFULLFEED9715081) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.